```html

Liver Inflammation (Hepatitis)

What is Liver Inflammation (Hepatitis)?

Hepatitis is the medical term for inflammation of the liver. The liver, a large organ located in the upper right abdomen, performs hundreds of vital functions—filtering toxins, producing bile for digestion, storing glycogen, and synthesizing clotting factors, among many others. When liver cells become inflamed, their ability to carry out these tasks is compromised. Hepatitis can be acute (lasting days to weeks) or chronic (lasting six months or longer). The condition may be mild and self‑limited, or it can progress to fibrosis, cirrhosis, and liver failure if left untreated.

Most sources, including the Mayo Clinic and the CDC, categorize hepatitis into several types based on cause—viral, alcoholic, autoimmune, metabolic, drug‑induced, and others.

Common Causes

Below are the most frequent triggers of liver inflammation. Some are infectious, while others relate to lifestyle, medications, or underlying disease.

• Viral hepatitis: Hepatitis A, B, C, D, and E viruses are the classic infectious agents.
• Alcoholic hepatitis: Excessive, long‑term alcohol consumption damages liver cells.
• Non‑alcoholic fatty liver disease (NAFLD) / Non‑alcoholic steatohepatitis (NASH): Fat accumulation and inflammation unrelated to alcohol.
• Autoimmune hepatitis: The immune system mistakenly attacks liver tissue.
• Drug‑induced (toxic) hepatitis: Over‑the‑counter pain relievers (acetaminophen), certain antibiotics, antiepileptics, and herbal supplements.
• Metabolic disorders: Hemochromatosis (iron overload), Wilson disease (copper accumulation), and alpha‑1 antitrypsin deficiency.
• Vascular conditions: Budd‑Chiari syndrome (blocked hepatic veins) and hepatic artery thrombosis.
• Infection other than viruses: Bacterial sepsis, parasitic infections (e.g., schistosomiasis, amebic liver abscess).
• Cholestatic diseases: Primary biliary cholangitis and primary sclerosing cholangitis can cause secondary hepatitis.
• Exposure to toxins: Aflatoxin‑contaminated foods, industrial chemicals (e.g., carbon tetrachloride), and certain mushroom poisons.

Associated Symptoms

Symptoms vary with the cause, severity, and whether the hepatitis is acute or chronic. Commonly reported signs include:

• Fatigue and generalized weakness
• Right‑upper‑quadrant abdominal discomfort or fullness
• Jaundice (yellowing of the skin and eyes)
• Dark urine and pale, clay‑colored stools
• Loss of appetite and unintended weight loss
• Nausea, vomiting, or occasional abdominal bloating
• Fever and chills (more typical with acute viral hepatitis)
• Joint or muscle aches (often seen with hepatitis B and C)
• Spider‑like vascular lesions (spider angiomas) and palmar erythema in chronic disease

Because many of these signs overlap with other conditions, a proper medical evaluation is essential.

When to See a Doctor

Prompt medical attention can prevent complications. Seek care if you experience any of the following:

• Persistent jaundice lasting more than a few days
• Severe upper‑right‑abdomen pain or tenderness
• Confusion, difficulty concentrating, or sudden changes in mental status (possible hepatic encephalopathy)
• Unexplained fever > 38 °C (100.4 °F) that lasts more than 48 hours
• Vomiting blood or passing black, tar‑like stools (indicating gastrointestinal bleeding)
• Rapid weight loss, swelling of the abdomen (ascites), or swelling in the legs
• History of recent travel to areas with high hepatitis‑A or -E prevalence, especially if you consumed unsafe food or water
• Known exposure to hepatitis‑B or –C (e.g., sharing needles, unprotected sex, or a household member diagnosed)

Diagnosis

Healthcare providers use a combination of history, physical exam, laboratory tests, and imaging to confirm hepatitis and identify its cause.

1. Laboratory Evaluation

• Liver function tests (LFTs): Elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are the hallmark of hepatocellular injury. Alkaline phosphatase (ALP) and γ‑glutamyl transferase (GGT) rise with cholestatic patterns.
• Serum bilirubin: Indicates the degree of jaundice and liver excretory function.
• Coagulation profile: Prothrombin time (INR) may be prolonged when synthetic function declines.
• Viral serologies: Hepatitis A IgM, hepatitis B surface antigen (HBsAg), hepatitis B core IgM, hepatitis C antibody and RNA PCR, etc.
• Autoimmune markers: Antinuclear antibody (ANA), smooth muscle antibody (SMA), liver‑kidney microsomal antibody (LKM‑1).
• Metabolic panels: Ferritin and transferrin saturation (iron overload), ceruloplasmin (Wilson disease), α‑1 antitrypsin level.

2. Imaging Studies

• Abdominal ultrasound: First‑line; assesses liver size, texture, presence of fatty infiltration, masses, or biliary obstruction.
• Elastography (FibroScan) or MRI‑based elastography: Non‑invasive measurement of liver stiffness to gauge fibrosis.
• CT scan or MRI: Used when complications such as abscesses or tumors are suspected.

3. Liver Biopsy (when needed)

Considered the gold standard for diagnosing the exact pattern of inflammation, fibrosis stage, and for differentiating overlapping conditions. It is usually reserved for ambiguous cases or when treatment decisions hinge on histology.

Treatment Options

Treatment is tailored to the underlying cause, severity, and whether the disease is acute or chronic.

1. General Measures (applicable to most types)

• Rest and hydration: Helps the liver recover, especially in acute viral hepatitis.
• Nutrition: A balanced diet rich in protein (unless contraindicated), complex carbohydrates, fruits, vegetables, and healthy fats. Consider a dietitian’s guidance for NAFLD/NASH.
• Avoid alcohol: Completely abstain; even moderate intake worsens inflammation.
• Medication review: Discontinue hepatotoxic drugs under physician supervision.
• Vaccination: Hepatitis A and B vaccines are recommended for patients with chronic liver disease.

2. Cause‑Specific Therapies

• Viral hepatitis
  • Hepatitis A: Usually self‑limited; supportive care only.
  • Hepatitis B: Antiviral agents such as tenofovir or entecavir for chronic infection; acute infection typically monitored unless severe.
  • Hepatitis C: Direct‑acting antivirals (DAAs) (e.g., sofosbuvir/ledipasvir) achieve > 95 % cure rates.
  • Hepatitis D: Requires treatment of underlying HBV plus pegylated interferon‑α; new agents (e.g., bulevirtide) are emerging.
  • Hepatitis E: Generally supportive; ribavirin may be used for chronic infection in immunocompromised patients.
• Alcoholic hepatitis
  • Complete abstinence from alcohol.
  • Corticosteroids (e.g., prednisolone) for severe cases (Maddrey’s Discriminant Function ≥ 32) after assessing infection risk.
  • Nutritional supplementation, especially with thiamine, folate, and zinc.
• Non‑alcoholic fatty liver disease / NASH
  • Weight loss of 7‑10 % of body weight improves histology.
  • Exercise: ≥150 minutes/week of moderate‑intensity aerobic activity.
  • Medical options: Vitamin E (in non‑diabetic patients), pioglitazone, or newer agents such as obeticholic acid (under investigation).
• Autoimmune hepatitis
  • First‑line: Prednisone or prednisolone, often combined with azathioprine.
  • Maintenance: Low‑dose steroids or steroid‑sparing agents (mycophenolate mofetil, calcineurin inhibitors).
• Drug‑induced hepatitis
  • Immediate cessation of the offending drug.
  • N‑acetylcysteine for acetaminophen overdose (ideally within 8 hours of ingestion).
  • Supportive care; in severe cases, consider liver transplantation.
• Metabolic disorders
  • Hemochromatosis: Regular phlebotomy to reduce iron stores.
  • Wilson disease: Chelating agents such as D‑penicillamine or trientine, and zinc supplementation.
  • Alpha‑1 antitrypsin deficiency: No specific therapy for the liver; transplant is an option for advanced disease.

3. Advanced Therapies

• Liver transplantation: Reserved for end‑stage cirrhosis, acute liver failure, or hepatocellular carcinoma when other treatments fail.
• Clinical trials: Numerous investigational drugs for NASH, autoimmune hepatitis, and viral hepatitis are ongoing; participation may be appropriate for select patients.

Prevention Tips

Preventing hepatitis largely hinges on lifestyle choices, vaccination, and safe practices.

• Vaccinate: Hepatitis A and B vaccines are safe, effective, and recommended for all adults, especially those with chronic liver disease.
• Practice safe sex: Use condoms and limit the number of partners to reduce HBV/HCV transmission.
• Never share needles or drug‑paraphernalia.
• Drink alcohol in moderation or abstain completely if you have liver disease.
• Maintain a healthy weight: Aim for BMI 18.5‑24.9; incorporate regular exercise and a Mediterranean‑style diet rich in fruits, vegetables, whole grains, fish, and olive oil.
• Be cautious with medications and supplements: Follow dosing guidelines, avoid excess acetaminophen (> 4 g/day), and discuss herbal products with your physician.
• Travel wisely: When visiting regions endemic for hepatitis A/E, consume only bottled or boiled water, peel fruits, and avoid raw seafood.
• Regular screening: At‑risk individuals (e.g., people who inject drugs, men who have sex with men, those with HIV) should undergo periodic hepatitis B and C testing.

Emergency Warning Signs

If any of the following develop suddenly, seek emergency medical care (call 911 or go to the nearest emergency department):

• Severe, persistent abdominal pain that does not improve with rest.
• Sudden onset of confusion, drowsiness, or unusual behavior (possible hepatic encephalopathy).
• Vomiting blood (hematemesis) or passing black, tarry stools (melena).
• Rapidly worsening jaundice with associated itching, swelling of the abdomen (ascites), or leg edema.
• High fever (> 39 °C / 102 °F) with chills, especially after recent travel or known hepatitis exposure.
• Signs of severe liver failure: bleeding gums, easy bruising, or a sudden drop in blood pressure.

Early recognition and treatment of hepatitis can dramatically improve outcomes and prevent long‑term complications such as cirrhosis and liver cancer. If you suspect liver inflammation, contact your healthcare provider promptly.

---

References: Mayo Clinic, CDC, World Health Organization, National Institutes of Health (NIH), Cleveland Clinic, and peer‑reviewed journals accessed up to May 2026.

```